ProVise Management Group LLC Acquires 13,891 Shares of Sanofi $SNY

ProVise Management Group LLC raised its holdings in Sanofi (NASDAQ:SNY) by 6.6% during the fourth quarter, Holdings Channel reports. The institutional investor owned 224,422 shares of the company’s stock after buying an additional 13,891 shares during the quarter. ProVise Management Group LLC’s holdings in Sanofi were worth $10,875,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Mondrian Investment Partners LTD acquired a new stake in shares of Sanofi in the 3rd quarter worth about $171,742,000. Raymond James Financial Inc. increased its holdings in Sanofi by 81.3% during the 2nd quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock worth $284,058,000 after purchasing an additional 2,635,867 shares in the last quarter. Thrivent Financial for Lutherans increased its holdings in Sanofi by 10,152.1% during the 3rd quarter. Thrivent Financial for Lutherans now owns 2,200,107 shares of the company’s stock worth $103,846,000 after purchasing an additional 2,178,647 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in Sanofi by 422.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,062,809 shares of the company’s stock valued at $50,165,000 after acquiring an additional 859,246 shares in the last quarter. Finally, Victory Capital Management Inc. raised its position in Sanofi by 133.3% in the third quarter. Victory Capital Management Inc. now owns 1,413,640 shares of the company’s stock worth $66,681,000 after acquiring an additional 807,767 shares during the period. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently commented on the company. TD Cowen reiterated a “hold” rating on shares of Sanofi in a research note on Tuesday, December 30th. Weiss Ratings upgraded Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, April 9th. Wall Street Zen cut Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 21st. Citigroup reissued a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. Finally, Barclays cut Sanofi from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, Sanofi presently has a consensus rating of “Hold” and an average target price of $54.00.

Key Headlines Impacting Sanofi

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Strong Q1 results: Sanofi beat consensus on both EPS and revenue (reported $2.18 EPS vs. $0.93 est.; revenue ~ $13.0B), driven by Dupixent and new launches, supporting an upbeat 2026 outlook. Sanofi’s first-quarter earnings edges past estimates
• Positive Sentiment: U.S. approval expansion for Dupixent: FDA cleared Dupixent as the first biologic for young children (2–11) with uncontrolled chronic spontaneous urticaria — supports future addressable market and long-term growth of a core franchise. Dupixent approved in the US for young children with uncontrolled CSU
• Positive Sentiment: CHMP recommends Cenrifki (tolebrutinib) for EU approval to treat secondary progressive MS without relapses — regulatory progress that could broaden neurology portfolio. CHMP recommends Cenrifki (tolebrutinib)
• Positive Sentiment: Label expansion wins: FDA expanded Tzield for pediatric use, adding another growth pathway in specialty medicines. Tzield gets FDA nod for kids
• Neutral Sentiment: €2.3 billion bond offering priced across 2029/2033/2037 tranches — proceeds earmarked for general corporate purposes; modestly increases debt but at market rates given Sanofi’s low leverage. Sanofi prices €2.3 billion bond offering
• Negative Sentiment: Sarclisa SC BLA delayed: FDA set a new decision date (July 2026) after a filing delay — pushes potential commercialization timeline and may defer expected revenues from that subcutaneous formulation. Sarclisa SC BLA faces delay

Sanofi Stock Performance

Sanofi stock opened at $46.78 on Friday. Sanofi has a fifty-two week low of $43.32 and a fifty-two week high of $55.73. The firm’s fifty day moving average price is $46.42 and its 200-day moving average price is $47.98. The stock has a market cap of $114.10 billion, a P/E ratio of 13.07, a price-to-earnings-growth ratio of 1.18 and a beta of 0.42. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.73 and a current ratio of 1.09.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Wednesday, June 3rd. Shareholders of record on Monday, May 4th will be paid a dividend of $2.4225 per share. This represents a dividend yield of 502.0%. This is a boost from Sanofi’s previous annual dividend of $2.04. The ex-dividend date of this dividend is Monday, May 4th. Sanofi’s payout ratio is 44.44%.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.